title: [The results of ovarian cancer therapy in the Hungarian Centers in 2002-2003].
abstract: Authors presented data of treatment results and course of disease in 487 ovarian cancer patients treated by primary surgery and paclitaxel-carboplatin combination chemotherapy between July 1, 2002 and December 31, 2003.
  
  
  METHODS
  Most of our patients (87.8%) belonged to the age-group between 40-70 years. Distribution of their histological diagnosis was as 69.6% serous, 10.7% mucinous, 5.1% endometrial and 4.7% undifferentiated carcinoma. The grade distribution was found as 8.4% grade 1, 40.9% grade 2 and 35.9% grade 3.
  
  
  RESULTS
  The primary surgery was evaluated as optimal in 41.7%, suboptimal in 37.3% and exploration was performed in 21.1%. Most patients started chemotherapy 20 days after surgery and 74.2% of them got six courses. During the evaluation period 61 intervallum laparotomies were performed, and resulted on 55.7% optimal debulking. Complete remission was found in 58.9%, and partial remission in 14.7% of patients. This treatment resulted on a complete remission in 40.9% at the follow-up of 12 months.
authors.forename: Tamás
authors.initials: T
authors.lastname: Pulay
authors.forename: Márta
authors.initials: M
authors.lastname: Baki
authors.forename: György
authors.initials: G
authors.lastname: Bodoky
authors.forename: Magdolna
authors.initials: M
authors.lastname: Dank
authors.forename: József
authors.initials: J
authors.lastname: Cseh
authors.forename: András
authors.initials: A
authors.lastname: Csejtei
authors.forename: Sándor
authors.initials: S
authors.lastname: Csömör
authors.forename: József
authors.initials: J
authors.lastname: Erfán
authors.forename: Olga
authors.initials: O
authors.lastname: Esik
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Faluhelyi
authors.forename: József
authors.initials: J
authors.lastname: Izsó
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Hernádi
authors.forename: Kinga
authors.initials: K
authors.lastname: Kammerer
authors.forename: Tamás
authors.initials: T
authors.lastname: Magyar
authors.forename: Arpád
authors.initials: A
authors.lastname: Mayer
authors.forename: Eva
authors.initials: E
authors.lastname: Megyery
authors.forename: Katalin
authors.initials: K
authors.lastname: Moskovits
authors.forename: Lajos
authors.initials: L
authors.lastname: Pécsi
authors.forename: Béla
authors.initials: B
authors.lastname: Pikó
authors.forename: Tamás
authors.initials: T
authors.lastname: Pintér
authors.forename: Agnes
authors.initials: A
authors.lastname: Ruzsa
authors.forename: András
authors.initials: A
authors.lastname: Szánthó
authors.forename: István
authors.initials: I
authors.lastname: Szántó
authors.forename: János
authors.initials: J
authors.lastname: Szántó
authors.forename: Miklós
authors.initials: M
authors.lastname: Szucs
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Tálos
authors.forename: László
authors.initials: L
authors.lastname: Thurzó
authors.forename: Miklós
authors.initials: M
authors.lastname: Kásler
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000628:therapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001948:Brenner Tumor / Q000628:therapy; D016190:Carboplatin / Q000008:administration & dosage; D002277:Carcinoma / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D018269:Carcinoma, Endometrioid / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D018284:Cystadenocarcinoma, Serous / Q000628:therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D010052:Ovariectomy; D017239:Paclitaxel / Q000008:administration & dosage; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D017239:Paclitaxel